CDE Reference Standards 101st Batch Seeks Public Feedback
Policy / Regulatory

CDE Reference Standards 101st Batch Seeks Public Feedback

Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval
CompanyDrug

Jemincare JMX-2005 PAD Injection Secures NMPA Clinical Trial Approval

J&J TREMFYA Pediatric Psoriasis EC Approval Targets First IL-23 Indication
CompanyDrug

J&J TREMFYA Pediatric Psoriasis EC Approval Targets First IL-23 Indication

Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results
CompanyDrug

Takeda Zasocitinib TYK2 Phase III Shows Positive Psoriasis Results

Lilly Imlunestrant Breast-Cancer EMBER-3 Shows 38% Risk Reduction
CompanyDrug

Lilly Imlunestrant Breast-Cancer EMBER-3 Shows 38% Risk Reduction

IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully
CompanyDrug

IVIEW GVB-2001 Gene Therapy Treats First POAG Patient Successfully

Novartis MSD Sanofi TrumpRx Deal Targets Medicaid Pricing
Company

Novartis MSD Sanofi TrumpRx Deal Targets Medicaid Pricing

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial
CompanyDrug

Novabio’s Treg Therapy NP001 Doses First ALS Patient in China Trial

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis
CompanyDrug

Grand Pharmaceutical’s TLX591‑CDx RDC Wins China Phase III for Prostate Cancer Diagnosis

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
CompanyDeals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
CompanyDeals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
CompanyDrug

Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT